Early Clinical (Phases 0 and I)Ensuring safety is of the utmost concern for any drug developer. Myriad RBM not only provides reliable services for safety assessment, but is a leader in developing new solutions. In conjunction with pharmaceutical companies and consortiums, Myriad RBM has helped create innovative tools to aid in setting new standards for testing in early clinical research. Click here to request a quote or for customer support.
|
|
Trust the data. We don’t just run kits – we develop, manufacture and validate our multiplexed assays to clinical laboratory standards. With Myriad RBM, you can move forward knowing that the data generated is sensitive, reliable and reproducible. We operate a CLIA-certified lab and can support GLP studies. Please see our 
Rely on our expertise. We’ve been doing this for over a decade, combining multiplex immunoassay technology with liquid handling automation and a clinical lab infrastructure to quickly deliver sensitive, reproducible results. Our platform provides cost-effective data supporting research at each stage of drug development. We can identify new biomarkers linked to your disease indication or the efficacy of your drug and we can provide testing services for those biomarkers throughout the development process. We also have biomarker panels with specific applications, such as KidneyMAP® for early detection of renal toxicity. Visit our 
